Epigenetic targeting therapies to overcome chemotherapy resistance

Curt Balch, Kenneth P. Nephew

Research output: Chapter in Book/Report/Conference proceedingChapter

17 Scopus citations

Abstract

It is now well established that epigenetic aberrations occur early in malignant transformation, raising the possibility of identifying chemopreventive compounds or reliable diagnostic screening using epigenetic biomarkers. Combinatorial therapies effective for the reexpression of tumor suppressors, facilitating resensitization to conventional chemotherapies, hold great promise for the future therapy of cancer. This approach may also perturb cancer stem cells and thus represent an effective means for managing a number of solid tumors. We believe that in the near future, anticancer drug regimens will routinely include epigenetic therapies, possibly in conjunction with inhibitors of stemness signal pathways, to effectively reduce the devastating occurrence of cancer chemotherapy resistance.

Original languageEnglish (US)
Title of host publicationEpigenetic Alterations in Oncogenesis
EditorsAdam Karpf
Pages285-311
Number of pages27
DOIs
StatePublished - Jan 1 2013

Publication series

NameAdvances in Experimental Medicine and Biology
Volume754
ISSN (Print)0065-2598

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Epigenetic targeting therapies to overcome chemotherapy resistance'. Together they form a unique fingerprint.

  • Cite this

    Balch, C., & Nephew, K. P. (2013). Epigenetic targeting therapies to overcome chemotherapy resistance. In A. Karpf (Ed.), Epigenetic Alterations in Oncogenesis (pp. 285-311). (Advances in Experimental Medicine and Biology; Vol. 754). https://doi.org/10.1007/978-1-4419-9967-2-14